Insights

Biomarker Opportunity NeuroDex offers blood-based biomarker platforms ExoSORT and LuminEV for neuron-derived exosome analysis across ALS, Parkinson's, Alzheimer's, and Lewy Body Dementia, presenting strong cross-disease collaboration and pharma/biotech partnerships for biomarker discovery and clinical development.

Clinical Validation With capabilities in biomarker discovery, clinical trial validation, and translational research, NeuroDex provides end-to-end support that appeals to pharmaceutical sponsors seeking robust, validated biomarkers to de-risk neurodegenerative disease trials.

Strategic Partnerships Recent MJFF funding and Netherlands biomarker initiatives indicate active collaboration potential with foundations and regional/European researchers, creating access points for co-development deals and grant-supported studies.

Growth Readiness Revenue in the low-to-mid single digits with a small team signals scalable partnerships and targeted engagements, where larger CROs or biotech incumbents may license or co-develop biomarkers to accelerate portfolio expansion.

Expansion Signals News about measuring amyloid fibril length and extracellular vesicle biomarkers points to expanding assay modalities and disease coverage, offering opportunities to upsell existing platforms or forge new multi-disease collaboration agreements.

Similar companies to NeuroDex

NeuroDex Tech Stack

NeuroDex uses 8 technology products and services including LinkedIn Ads, HubSpot Analytics, Wix, and more. Explore NeuroDex's tech stack below.

NeuroDex's Email Address Formats

NeuroDex uses at least 2 email formats:
NeuroDex Email FormatsExamplePercentage
FLast@neurodex.coJDoe@neurodex.co
97%
First.Last@neurodex.coJohn.Doe@neurodex.co
3%

Frequently Asked Questions

What is NeuroDex's official website and social media links?

Minus sign iconPlus sign icon
NeuroDex's official website is neurodex.co and has social profiles on LinkedIn and Crunchbase.

How much revenue does NeuroDex generate?

Minus sign iconPlus sign icon
As of October 2026, NeuroDex's annual revenue is estimated to be $1M - $10M.

What is NeuroDex's SIC code and NAICS code?

Minus sign iconPlus sign icon
NeuroDex's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NeuroDex have currently?

Minus sign iconPlus sign icon
As of October 2026, NeuroDex has approximately 15 employees across 1 continents, including North America. Key team members include : E. V. B. Explore NeuroDex's employee directory with LeadIQ.

What industry does NeuroDex belong to?

Minus sign iconPlus sign icon
NeuroDex operates in the Biotechnology Research industry.

What technology does NeuroDex use?

Minus sign iconPlus sign icon
NeuroDex's tech stack includes LinkedIn Ads, HubSpot Analytics, Wix, WordPress, CookieYes, Shopify, WooCommerce and Google Cloud.

What is NeuroDex's email format?

Minus sign iconPlus sign icon
NeuroDex's email format typically follows the pattern of FLast@neurodex.co. Find more NeuroDex email formats with LeadIQ.

When was NeuroDex founded?

Minus sign iconPlus sign icon
NeuroDex was founded in 2018.
NeuroDex logo

NeuroDex

Biotechnology ResearchMassachusetts, United States11-50 Employees

NeuroDex is a biotechnology company focused on developing blood-based diagnostics for neurodegenerative disorders. Its core approach centers on isolating neuronal-derived exosomes from blood and analyzing them to support neurological research and development, with collaborations that broaden access to its platform for advancing studies in the field.
Based in Natick, Massachusetts, the company positions itself within the biotechnology research sector by offering biomarkers and an exosome-based broad biomarker program aimed at identifying neurodegenerative conditions and differentiating related dementias. The business serves researchers and collaborators seeking objective, minimally invasive insights into neurological disease processes, including Parkinson’s disease and other synucleinopathies, through its extracellular vesicle–led assays. A recent development includes ongoing work announced in 2026 around measuring amyloid fibril characteristics as part of biomarker efforts, reflecting a continued focus on blood-based indicators for neurodegenerative disorders.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    NeuroDex's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.